Bayer

News

AHA: First data backs AskBio’s heart failure gene therapy

Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse event

News

Bayer pledges up to $1.5bn for Recursion oncology alliance

Bayer has restructured and expanded its ongoing partnership with Recursion Pharmaceuticals on artificial intelligence-powered drug discovery, switching to a focus on cance

News

Bayer to streamline management in cost-cutting drive

Bayer’s new chief executive Bill Anderson has launched a “re-design” of Bayer that will see layers of management stripped out by the end of next year, with “95% of the dec

News

Bayer adds a new life science incubator in China

Bayer’s network of Co.Lab life sciences incubators has expanded once again with the announcement of a new site in Shanghai, China, that will focus on oncology cell and gen

News

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe

News

Bayer launches support tool for diabetic kidney disease

Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression t

AHA: First data backs AskBio’s heart failure gene therapy

Bayer pledges up to $1.5bn for Recursion oncology alliance

Bayer to streamline management in cost-cutting drive

Bayer adds a new life science incubator in China

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer launches support tool for diabetic kidney disease

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Bayer

Editor's Picks